论文部分内容阅读
欧洲药品局(EMEA)近日通知罗氏(Roche)公司已接受有关口服癌症治疗药物Xeloda(希罗达)与另一种化疗药物顺铂(cisplatin)联合用于新适用症晚期胃癌的申请。胃癌在最常见的确诊癌症中位居第四,且是全球癌症相关死亡的第二大致病因素。该申请基于希罗达/顺铂与现行标准疗法5-氟尿嘧啶(5-Fluorouracil,5-FU)加顺铂(作为晚期胃癌的一线疗法)的疗效和安全性的Ⅲ期研究结果的调查;该结果证实接受Xeloda/顺铂联合疗法的患者的存活时间至少与那些接受现行标准疗法的患
The European Medicines Agency (EMEA) recently notified Roche that it has accepted an application for a combination of Xeloda, an oral cancer drug, and cisplatin, another chemotherapeutic drug, for newly diagnosed advanced gastric cancer. Gastric cancer ranks fourth in the most commonly diagnosed cancers and is the second most common cause of cancer-related deaths worldwide. This application is based on a survey of the results of Phase III studies of the efficacy and safety of Xeloda / cisplatin with current standard therapies for 5-Fluorouracil (5-FU) plus cisplatin (first-line therapy for advanced gastric cancer) The results confirm that patients who received Xeloda / cisplatin combination therapy had at least as long survival as those who received current standard therapies